ARTICLE | Company News
OncoImmune, Pfizer deal
September 19, 2016 7:00 AM UTC
OncoImmune granted Pfizer an exclusive option to license rights to ONC-392, a preclinical mAb against cytotoxic T-lymphocyte associated protein 4 ( CTLA4; CD152), and additional anti-CTLA4 antibodi...